Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir alafenamide conversion in liver transplant patients
KCT0009960Phase 2Not yet recruiting
- Sponsor
- Dong-A ST
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tenofovir alafenamide in hepatitis B (HBV), chronic kidney disease (CKD), sponsored by Dong-A ST. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)chronic kidney disease (CKD)
Beyond the preview
Go deeper on KCT0009960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009960.